Bio-Bridge Science, Inc. (OTC BB: BGES)

Bio-Bridge Science, Inc. (OTC BB: BGES) is a development stage biotechnology company committed to engaging in the commercial development of vaccines for the prevention and treatment of human infectious diseases. Currently, the company is focused on developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). The HIV vaccines developed by Bio-Bridge are designed for both preventive and therapeutic purposes. For further information, visit the Company’s web site at www.bio-bridge-science.com.